Serum Uric Acid in Patients with Parkinson’s Disease and Vascular Parkinsonism: A Cross-Sectional Study
暂无分享,去创建一个
Aimin Wu | Mei Liu | B. Tang | Xiaohong Chen | Beisha Tang | A. Wu | Mengqiu Pan | Huimin Gao | Ling Long | Yunqi Xu | Jing Zou | Xiaobo Wei | Xiaohong Chen | Qing Wang | Yunqi Xu | L. Long | Xiaobo Wei | Huimin Gao | Qing Wang | Mengqiu Pan | Jing Zou | Mei Liu
[1] Ying Jiang,et al. The Combination of Homocysteine and C-Reactive Protein Predicts the Outcomes of Chinese Patients with Parkinson's Disease and Vascular Parkinsonism , 2011, PloS one.
[2] Gang Wang,et al. Kinases and kinase signaling pathways: Potential therapeutic targets in Parkinson's disease , 2012, Progress in Neurobiology.
[3] I. Schlesinger,et al. Uric acid in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.
[4] Y. Chan,et al. Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. , 2010, Free radical biology & medicine.
[5] S. Przedborski,et al. Oxidative Stress in Parkinson's Disease , 2008, Annals of the New York Academy of Sciences.
[6] A. Schapira. OXIDATIVE STRESS IN PARKINSONS-DISEASE , 1995 .
[7] W. Wurst,et al. Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor α in the nigrostriatal dopaminergic circuit of adult mice , 2011, Experimental Neurology.
[8] M. Walters,et al. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? , 2006, British journal of clinical pharmacology.
[9] M. Pohja,et al. Uric acid and cognition in Parkinson's disease: a follow-up study. , 2011, Parkinsonism & related disorders.
[10] A. Hofman,et al. Serum uric acid levels and the risk of Parkinson disease , 2005, Annals of neurology.
[11] E. Esposito,et al. Non-steroidal anti-inflammatory drugs in Parkinson's disease , 2007, Experimental Neurology.
[12] M. Mattson,et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease , 2002, Journal of neurochemistry.
[13] G. Bing,et al. Striatal Neuroinflammation Promotes Parkinsonism in Rats , 2008, PloS one.
[14] S. Przedborski. Inflammation and Parkinson's disease pathogenesis , 2010, Movement disorders : official journal of the Movement Disorder Society.
[15] A. Lang,et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. , 2008, Archives of neurology.
[16] C. Tanner,et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. , 2009, Archives of neurology.
[17] J. Trojanowski,et al. Mechanisms of Parkinson's Disease Linked to Pathological α-Synuclein: New Targets for Drug Discovery , 2006, Neuron.
[18] M. Hoehn,et al. Parkinsonism , 1967, Neurology.
[19] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[20] E. Hirsch,et al. Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.
[21] A. Lang. A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials , 2011, Movement disorders : official journal of the Movement Disorder Society.
[22] D. Bennett,et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.
[23] M. Mcdermott,et al. The relationship between uric acid levels and Huntington's disease progression , 2010, Movement disorders : official journal of the Movement Disorder Society.
[24] D. Spiegelman,et al. Plasma urate and Parkinson's disease in women. , 2010, American journal of epidemiology.
[25] A. Shankar,et al. Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community‐based survey , 2010, Movement disorders : official journal of the Movement Disorder Society.
[26] E. Hirsch,et al. Protection of midbrain dopaminergic neurons by the end‐product of purine metabolism uric acid: potentiation by low‐level depolarization , 2009, Journal of neurochemistry.
[27] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[28] Á. Chamorro,et al. Prognostic Significance of Uric Acid Serum Concentration in Patients With Acute Ischemic Stroke , 2002, Stroke.
[29] Melinda K. Kutzing,et al. Altered Uric Acid Levels and Disease States , 2008, Journal of Pharmacology and Experimental Therapeutics.
[30] R. Rosenfeld. Patients , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[31] Z. Pei,et al. Nonmotor symptoms are independently associated with impaired health‐related quality of life in Chinese patients with Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[32] M. Weisskopf,et al. Plasma urate and risk of Parkinson's disease. , 2007, American journal of epidemiology.
[33] R. Brinton,et al. Mitochondria as therapeutic targets of estrogen action in the central nervous system. , 2004, Current drug targets. CNS and neurological disorders.
[34] S. Kish,et al. Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.
[35] Hirotaka Matsuo,et al. Molecular identification of a renal urate–anion exchanger that regulates blood urate levels , 2002, Nature.
[36] W. H. Church,et al. Uric acid is reduced in the substantia nigra in parkinson's disease: Effect on dopamine oxidation , 1994, Brain Research Bulletin.
[37] Ying Xia,et al. Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease , 2012, Progress in Neurobiology.
[38] V. Trkulja,et al. Impact of pre-morbid depression on health-related quality of life in non-demented Parkinson's disease patients. , 2010, Parkinsonism & related disorders.
[39] Andrew J Lees,et al. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis , 2004, Movement disorders : official journal of the Movement Disorder Society.
[40] J. Hare,et al. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications , 2004, The Journal of physiology.
[41] B. Djahanguiri,et al. The prevention of acute gastric ulcer in the rat by alpha-methyldopa. , 1967, Medicina et pharmacologia experimentalis. International journal of experimental medicine.
[42] H. Benamer,et al. Vascular Parkinsonism: A Clinical Review , 2008, European Neurology.
[43] N. Hattori,et al. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease]. , 2004, Rinsho shinkeigaku = Clinical neurology.
[44] Á. Chamorro,et al. Uric Acid Levels Are Relevant in Patients With Stroke Treated With Thrombolysis , 2011, Stroke.
[45] Paolo Barone,et al. The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study , 2007, Movement disorders : official journal of the Movement Disorder Society.
[46] M. Tansey,et al. Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention , 2007, Experimental Neurology.
[47] Honglei Chen,et al. Peripheral Inflammatory Biomarkers and Risk of Parkinson's Disease , 2007 .
[48] P. Mecocci,et al. Antioxidant Profile and Early Outcome in Stroke Patients , 2000, Stroke.
[49] A. Hofman,et al. Serum uric acid and cognitive function and dementia. , 2008, Brain : a journal of neurology.